Local hyperemia to heating is impaired in secondary Raynaud's phenomenon

Aude Boignard, Muriel Salvat-Melis, Patrick H Carpentier, Christopher T Minson, Laurent Grange, Catherine Duc, Françoise Sarrot-Reynauld, Jean-Luc Cracowski, Aude Boignard, Muriel Salvat-Melis, Patrick H Carpentier, Christopher T Minson, Laurent Grange, Catherine Duc, Françoise Sarrot-Reynauld, Jean-Luc Cracowski

Abstract

Accurate and sensitive measurement techniques are a key issue in the quantification of the microvascular and endothelial dysfunction in systemic sclerosis (SSc). Thermal hyperemia comprises two separate mechanisms: an initial peak that is axon reflex mediated; and a sustained plateau phase that is nitric oxide dependent. The main objective of our study was to test whether thermal hyperemia in patients with SSc differed from that in patients with primary Raynaud's phenomenon (RP) and healthy controls. In a first study, we enrolled 20 patients suffering from SSc, 20 patients with primary RP and 20 healthy volunteers. All subjects were in a fasting state. Post-occlusive hyperemia, 0.4 mg sublingual nitroglycerin challenge and thermal hyperemia were performed using laser Doppler flowmetry on the distal pad of the third left finger. In a second study, thermal hyperemia was performed in 10 patients with rheumatoid arthritis and 10 patients with primary RP. The thermal hyperemia was dramatically altered in terms of amplitude and kinetics in patients with SSc. Whereas 19 healthy volunteers and 18 patients with primary RP exhibited the classic response, including an initial peak within the first 10 minutes followed by a nadir and a second peak, this occurred only in four of the SSc patients (p < 0.0001). The 10 minutes thermal peak was 43.4 (23.2 to 63), 42.6 (31 to 80.7) and 27 (14.7 to 51.4) mV/mm Hg in the healthy volunteers, primary RP and SSc groups, respectively (p = 0.01), while the 44 degrees C thermal peak was 43.1 (21.3 to 62.1), 42.6 (31.6 to 74.3) and 25.4 (15 to 52.4) mV/mm Hg, respectively (p = 0.01). Thermal hyperemia was more sensitive and specific than post-occlusive hyperhemia for differentiating SSc from primary RP. In patients with rheumatoid arthritis, thermal hyperemia was also altered in terms of amplitude. Thermal hyperemia is dramatically altered in patients with secondary RP in comparison with subjects with primary RP. Further studies are required to determine the mechanisms of this altered response, and whether it may provide additional information in a clinical setting.

Figures

Figure 1
Figure 1
Thermal hypermemia in Raynaud's phenomenon (RP), limited and diffuse cutaneous systemic sclerosis (lcSSc and dcSSc). The patient with primary Raynaud's phenomenon has a normal response, including a first peak within the first 10 minutes and a nadir followed by a second plateau. This response is altered in the lcSSc patient, in which neither the initial cutaneous vascular conductance peak nor nadir is observed. The dcSSc patient shows a destructured response, including a delayed maximal response.
Figure 2
Figure 2
Amplitude of the thermal hyperhemia in systemic sclerosis (SSc) and rheumatoid arthritis. (a) Patients with systemic sclerosis (SSc), primary Raynaud's phenomenon (RP) and healthy controls. (b) Patients with rheumatoid arthritis (RA) and primary RP. Data are expressed as box plots in which 50% of values lie within the box. The horizontal line depicts the median value and the whiskers indicate the 10th and the 90th percentiles of all values.

References

    1. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol. 2000;12:527–533. doi: 10.1097/00002281-200011000-00009.
    1. Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am. 1990;16:75–91.
    1. Freedman RR, Girgis R, Mayes MD. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J Rheumatol. 2001;28:119–121.
    1. Stummvoll GH, Aringer M, Grisar J, Steiner CW, Smolen JS, Knobler R, Graninger WB. Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis. 2004;63:569–574. doi: 10.1136/ard.2002.004838.
    1. Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology (Oxford) 2002;41:843–847. doi: 10.1093/rheumatology/41.8.843.
    1. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet. 2004;364:603–610. doi: 10.1016/S0140-6736(04)16853-0.
    1. Schlez A, Kittel M, Braun S, Hafner HM, Junger M. Endothelium-dependent regulation of cutaneous microcirculation in patients with systemic scleroderma. J Invest Dermatol. 2003;120:332–334. doi: 10.1046/j.1523-1747.2003.12023.x.
    1. Hahn M, Heubach T, Steins A, Junger M. Hemodynamics in nailfold capillaries of patients with systemic scleroderma: synchronous measurements of capillary blood pressure and red blood cell velocity. J Invest Dermatol. 1998;110:982–985. doi: 10.1046/j.1523-1747.1998.00190.x.
    1. Anderson ME, Moore TL, Hollis S, Clark S, Jayson MI, Herrick AL. Endothelial-dependent vasodilation is impaired in patients with systemic sclerosis, as assessed by low dose iontophoresis. Clin Exp Rheumatol. 2003;21:403.
    1. Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol. 1998;82:1555–1557. doi: 10.1016/S0002-9149(98)00708-5. A1558.
    1. Creutzig A, Hiller S, Appiah R, Thum J, Caspary L. Nailfold capillaroscopy and laser Doppler fluxmetry for evaluation of Raynaud's phenomenon: how valid is the local cooling test? Vasa. 1997;26:205–209.
    1. Rajagopalan S, Pfenninger D, Kehrer C, Chakrabarti A, Somers E, Pavlic R, Mukherjee D, Brook R, D'Alecy LG, Kaplan MJ. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum. 2003;48:1992–2000. doi: 10.1002/art.11060.
    1. Cracowski JL, Carpentier PH, Imbert B, Cachot S, Stanke-Labesque F, Bessard J, Bessard G. Increased urinary F2-isoprostanes in systemic sclerosis but not in primary Raynaud's phenomenon, effect of a cold exposure. Arthritis Rheum. 2002;46:1319–1323. doi: 10.1002/art.10261.
    1. Wigley FM, Wise RA, Mikdashi J, Schaefer S, Spence RJ. The post-occlusive hyperemic response in patients with systemic sclerosis. Arthritis Rheum. 1990;33:1620–1625.
    1. Morf S, Amann-Vesti B, Forster A, Franzeck UK, Koppensteiner R, Uebelhart D, Sprott H. Microcirculation abnormalities in patients with fibromyalgia – measured by capillary microscopy and laser fluxmetry. Arthritis Res Ther. 2005;7:R209–R216. doi: 10.1186/ar1459.
    1. Binggeli C, Spieker LE, Corti R, Sudano I, Stojanovic V, Hayoz D, Luscher TF, Noll G. Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: a monitoring test of endothelial dysfunction for clinical practice? J Am Coll Cardiol. 2003;42:71–77. doi: 10.1016/S0735-1097(03)00505-9.
    1. Celermajer DS. Statins, skin, and the search for a test of endothelial function. J Am Coll Cardiol. 2003;42:78–80. doi: 10.1016/S0735-1097(03)00508-4.
    1. Wong BJ, Wilkins BW, Holowatz LA, Minson CT. Nitric oxide synthase inhibition does not alter the reactive hyperemic response in the cutaneous circulation. J Appl Physiol. 2003;95:504–510.
    1. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc. 2003;78:603–612.
    1. Minson CT, Berry LT, Joyner MJ. Nitric oxide and neurally mediated regulation of skin blood flow during local heating. J Appl Physiol. 2001;91:1619–1626.
    1. Stewart J, Kohen A, Brouder D, Rahim F, Adler S, Garrick R, Goligorsky MS. Noninvasive interrogation of microvasculature for signs of endothelial dysfunction in patients with chronic renal failure. Am J Physiol Heart Circ Physiol. 2004;287:H2687–H2696. doi: 10.1152/ajpheart.00287.2004.
    1. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis Rheum. 1980;23:581–590.
    1. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205.
    1. Furst DE, Clements PJ, Steen VD, Medsger TA, Jr, Masi AT, D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1998;25:84–88.
    1. Leroy EC, Medsger TA., Jr Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485–488.
    1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324.
    1. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–265. doi: 10.1016/S0735-1097(01)01746-6.
    1. Zhao JL, Pergola PE, Roman LJ, Kellogg DL., Jr Bioactive nitric oxide concentration does not increase during reactive hyperemia in human skin. J Appl Physiol. 2004;96:628–632. doi: 10.1152/japplphysiol.00639.2003.
    1. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106:2184–2187. doi: 10.1161/01.CIR.0000037521.71373.44.
    1. Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, Spieker LE, Frey D, Hermann M, Riesen W, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol. 2005;45:461–464. doi: 10.1016/j.jacc.2004.11.006.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel